Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 11/20 | 0.73 |
| ▸ | CDK1 | P06493 | 4/20 | 0.73 |
| ▸ | CDK9 | P50750 | 4/20 | 0.73 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.73 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.73 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.73 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.73 |
| ▸ | CDK7 | P50613 | 3/20 | 0.61 |
| ▸ | CCNH | P51946 | 2/20 | 0.61 |
| ▸ | IKBKB | O14920 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | DKK1 | O94907 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | NEK2 | P51955 | 2/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29739855 | 0.87 | CDK2 (0.56) | CDK2CDK1CDK9CCNT1CCNB1 | |
| SCHEMBL28765782 | 0.87 | CDK2 (0.56) | CDK2CDK1CDK9CCNT1CCNB1 | |
| SCHEMBL29883031 | 0.84 | CDK2 (1.00) | CDK2CDK1CDK9CCNT1CCNB1 | |
| SCHEMBL27784897 | 0.79 | CDK2 (0.47) | CDK2CDK1CDK9CCNT1CCNB1 | |
| SCHEMBL27784961 | 0.79 | TNNI3K (0.47) | CDK2CDK1CDK9CCNT1CCNB1 | |
| SCHEMBL3016858 | 0.79 | CDK2 (0.53) | CDK2CDK1CDK9CCNT1CCNB1 | |
| SCHEMBL3025941 | 0.77 | CDK2 (0.46) | CDK2CDK1CDK9CCNT1CCNB1 | |
| SCHEMBL3028140 | 0.76 | TNNI3K (0.46) | CDK2CDK1CDK9CCNT1CCNB1 | |
| SCHEMBL28780326 | 0.75 | TNNI3K (0.47) | CDK2CDK1CDK9CCNT1CCNB1 | |
| SCHEMBL3025649 | 0.74 | SYK (0.45) | CDK2CDK1CDK9CCNT1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | CDK2 2103/4885CDK1 2489/4885CDK9 2031/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | CDK2 1489/4885CDK1 1952/4885CDK9 2993/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | CDK2 1489/4885CDK1 1952/4885CDK9 2993/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | CDK2 1540/4885CDK1 2448/4885CDK9 2873/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | CDK2 1981/4885CDK1 2325/4885CDK9 2660/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | CDK2 2992/4885CDK1 3347/4885CDK9 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.